JPH11170A - デスドメイン含有受容体 - Google Patents

デスドメイン含有受容体

Info

Publication number
JPH11170A
JPH11170A JP9057503A JP5750397A JPH11170A JP H11170 A JPH11170 A JP H11170A JP 9057503 A JP9057503 A JP 9057503A JP 5750397 A JP5750397 A JP 5750397A JP H11170 A JPH11170 A JP H11170A
Authority
JP
Japan
Prior art keywords
amino acid
polypeptide
seq
nucleotide sequence
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9057503A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11170A5 (enExample
Inventor
Guo-Liang Yu
グオ−リェン・ユ
Jian Ni
ジェン・ニ
Vishva Dixit
ビシュバ・ディキシット
Reiner L Gentz
レイナー・エル・ジェンツ
Patrick J Dillon
パトリック・ジェイ・ディロン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
University of Michigan Ann Arbor
Original Assignee
Human Genome Sciences Inc
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, University of Michigan Ann Arbor filed Critical Human Genome Sciences Inc
Publication of JPH11170A publication Critical patent/JPH11170A/ja
Publication of JPH11170A5 publication Critical patent/JPH11170A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
JP9057503A 1996-03-12 1997-03-12 デスドメイン含有受容体 Pending JPH11170A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US1328596P 1996-03-12 1996-03-12
US2871196P 1996-10-17 1996-10-17
US3734197P 1997-02-06 1997-02-06
US60/013285 1997-02-06
US60/028711 1997-02-06
US60/037341 1997-02-06

Publications (2)

Publication Number Publication Date
JPH11170A true JPH11170A (ja) 1999-01-06
JPH11170A5 JPH11170A5 (enExample) 2005-02-10

Family

ID=27359824

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9057503A Pending JPH11170A (ja) 1996-03-12 1997-03-12 デスドメイン含有受容体

Country Status (3)

Country Link
US (3) US6153402A (enExample)
JP (1) JPH11170A (enExample)
WO (1) WO1997033904A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025018311A1 (ja) 2023-07-14 2025-01-23 旭化成株式会社 金属複合材料

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198640A1 (en) * 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
JP2000507829A (ja) * 1996-04-01 2000-06-27 ジェネンテック インコーポレーテッド Apo―2liおよびapo―3アポトーシスポリペプチド
US20020165157A1 (en) * 1996-04-01 2002-11-07 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
US6462176B1 (en) * 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
AU718474B2 (en) * 1996-10-04 2000-04-13 Immunex Corporation Novel receptor that causes cell death
US6297022B1 (en) 1997-10-08 2001-10-02 Smithkline Beecham Corporation Method of identifying agonists and antagonists for tumor necrosis related receptor TR1
EP1054961A2 (en) * 1998-02-17 2000-11-29 Incyte Pharmaceuticals, Inc. Human short-chain tnf-receptor family protein
US20030078211A1 (en) * 1998-06-24 2003-04-24 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
WO2001077137A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
EP1178815A4 (en) * 1999-04-22 2003-02-05 Human Genome Sciences Inc THE "DEATH DOMAIN" RECEPTORS
US6482411B1 (en) * 1999-08-27 2002-11-19 Board Of Regents, The University Of Texas System Methods of reducing bone loss with CD40 ligand
US6994976B1 (en) 1999-11-19 2006-02-07 Tittle Thomas V Tr3-specific binding agents and methods for their use
EP1231937A2 (en) * 1999-11-19 2002-08-21 Thomas V. Tittle Tr3-specific binding agents and methods for their use
EP2431054A3 (en) 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
KR20060088905A (ko) 2000-06-16 2006-08-07 휴먼 게놈 사이언시즈, 인코포레이티드 면역특이적으로 BLyS에 결합하는 항체
CA2426765C (en) 2000-10-24 2012-06-05 Shunichi Shiozawa Genomes participating in rheumatoid arthritis, method of the diagnosis thereof, method of evaluating the onset possibility thereof, diagnostic kit for detecting them and therapeutic method and remedies for rheumatoid arthritis
US6965023B2 (en) * 2000-11-17 2005-11-15 The Burnham Institute Death domain proteins
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
ES2428321T3 (es) * 2003-08-20 2013-11-07 University Of Miami Composiciones y métodos para tratar la enfermedad del pulmón inflamado
ES2611307T3 (es) 2005-08-30 2017-05-08 University Of Miami Inmunomodulación de agonistas, antagonistas e inmunotoxinas del receptor del factor de necrosis tumoral 25 (TNFR25)
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
US9896511B2 (en) 2007-01-10 2018-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
JP5684130B2 (ja) 2008-09-26 2015-03-11 トカジェン インコーポレーテッド 組換えベクター
CN102770455B (zh) 2009-08-03 2017-02-08 迈阿密大学 用于体内扩增调节性t细胞的方法
KR101919170B1 (ko) 2010-11-19 2018-11-15 에자이 알앤드디 매니지먼트 가부시키가이샤 중화 항-ccl20 항체
US9737612B2 (en) 2011-03-01 2017-08-22 Novo Nordisk A/S Antagonistic DR3 ligands
CA2836898A1 (en) 2011-05-20 2012-11-29 Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
EP3623478A1 (en) 2012-10-25 2020-03-18 Tocagen Inc. Retroviral vector with mini-promoter cassette
WO2014110258A1 (en) 2013-01-09 2014-07-17 Podack Eckhard R Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein
US20160067337A1 (en) 2013-03-14 2016-03-10 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0103960B1 (en) * 1982-07-30 1991-01-23 Mach, Bernard François, Prof. Dna sequences coding for the dr beta-chain locus of the human lymphocyte antigen complex and polypeptides, diagnostic typing processes and products related thereto
US5120525A (en) 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
IL106271A (en) * 1992-09-03 2008-03-20 Yeda Res & Dev Ligand to TNF 75P receptor and its preparation
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5464938A (en) * 1990-04-09 1995-11-07 Immunex Corporation Isolated viral protein TNF antagonists
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
DE69229454T2 (de) 1991-03-28 2000-01-05 Merck & Co., Inc. Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
WO1994009137A1 (en) * 1992-10-15 1994-04-28 Genentech, Inc. Antibodies against type 2 tumor necrosis factor receptor
JPH08507201A (ja) * 1992-12-04 1996-08-06 バイオジェン,インコーポレイテッド リンホトキシン‐β、リンホトキシン‐β複合体、それらの薬学的な調製物および治療への使用
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
CA2174132A1 (en) 1993-10-14 1995-04-20 Immunex Corporation Fas antagonists and uses thereof
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6599719B2 (en) 1994-11-07 2003-07-29 Human Genome Sciences, Inc. Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha
ES2285701T3 (es) 1994-11-07 2007-11-16 Human Genome Sciences, Inc. Factor-gamma de necrosis tumoral.
US5928939A (en) 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
WO1996034095A1 (en) 1995-04-27 1996-10-31 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
EP0904278A4 (en) 1996-03-22 1999-09-15 Human Genome Sciences Inc MOLECULE II INDUCER OF APOPTOSIS
JP2000507829A (ja) * 1996-04-01 2000-06-27 ジェネンテック インコーポレーテッド Apo―2liおよびapo―3アポトーシスポリペプチド
DE69733204T3 (de) 1996-07-15 2012-03-08 Chugai Seiyaku K.K. Neuartige vegf-ähnliche faktoren
CA2260754C (en) 1996-07-15 2012-01-24 Chugai Research Institute For Molecular Medicine, Inc. Novel vegf-like factor
ES2316153T3 (es) 1996-08-16 2009-04-01 Human Genome Sciences, Inc. Endoquina alfa humana.
AU4055697A (en) 1996-08-16 1998-03-06 Schering Corporation Mammalian cell surface antigens; related reagents
CA2263890C (en) 1996-08-23 2013-05-14 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
AU718474B2 (en) * 1996-10-04 2000-04-13 Immunex Corporation Novel receptor that causes cell death
CA2266439C (en) 1996-10-25 2009-06-16 Human Genome Sciences, Inc. Neutrokine .alpha.
WO1998030693A2 (en) 1997-01-14 1998-07-16 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
KR20000070174A (ko) 1997-01-14 2000-11-25 벤슨 로버트 에이치. 종양 괴사 인자 수용체 6α 및 6β
JP4450870B2 (ja) 1997-01-28 2010-04-14 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 死ドメイン含有レセプター4(dr4:死レセプター4)、tnf−レセプタースーパーファミリーのメンバーおよびtrailへの結合
DE69800640T2 (de) 1997-01-29 2001-07-05 Polymasc Pharmaceuticals Plc, London Pegylationsverfahren
KR100527638B1 (ko) 1997-03-17 2005-11-23 휴먼 게놈 사이언시즈, 인코포레이티드 사망 도메인을 보유하는 수용체 5
EP0980432A1 (en) 1997-05-01 2000-02-23 Amgen, Inc. Chimeric opg polypeptides
JP2002503963A (ja) 1997-06-11 2002-02-05 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ヒト腫瘍壊死因子受容体tr9

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025018311A1 (ja) 2023-07-14 2025-01-23 旭化成株式会社 金属複合材料

Also Published As

Publication number Publication date
US20030077694A1 (en) 2003-04-24
US6759513B2 (en) 2004-07-06
WO1997033904A1 (en) 1997-09-18
US20020009773A1 (en) 2002-01-24
US6951735B2 (en) 2005-10-04
US6153402A (en) 2000-11-28

Similar Documents

Publication Publication Date Title
US6759513B2 (en) Death domain containing receptors
JP4450870B2 (ja) 死ドメイン含有レセプター4(dr4:死レセプター4)、tnf−レセプタースーパーファミリーのメンバーおよびtrailへの結合
JP4330180B2 (ja) 死ドメイン含有レセプター5
US6261801B1 (en) Nucleic acids encoding tumor necrosis factor receptor 5
JP2001507937A (ja) 腫瘍壊死因子レセプター6αおよび腫瘍壊死因子レセプター6β
JP2002511070A (ja) ヒト腫瘍壊死因子受容体tr10
JP2002503963A (ja) ヒト腫瘍壊死因子受容体tr9
EP1788086A1 (en) Death Domain Containing Receptor 5
EP0898576A1 (en) Death domain containing receptors
MXPA99008486A (en) Death domain containing receptor 5
HK1025352B (en) Death domain containing receptor 5
AU2006246525A1 (en) Death Domain Containing Receptor 5

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060620

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060920

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060925

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070306